Physician profile
Devaraj Munikrishnappa
NPI 1467537167
$6,094.45
in general payments reported to CMS, 2019-2025
30 companies · $1,213 in 2025
The $1,213 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $676 · 2020: $620 · 2021: $559 · 2022: $953 · 2023: $597 · 2024: $1,477 · 2025: $1,213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,251 · Education: $36.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,251.11 |
| Education | $36.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,077.23 | 2019-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $799.65 | 2019-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $538.19 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $498.48 | 2019-2025 | Veltassa |
| Amgen INC. | $365.44 | 2022-2025 | Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $276.98 | 2024-2025 | |
| Opko Pharmaceuticals, LLC | $266.46 | 2020-2025 | Rayaldee |
| Calliditas Therapeutics US INC. | $251.31 | 2022-2024 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $237.42 | 2020-2022 | |
| Medtronic, INC. | $213.68 | 2023-2024 | Ellipsys Vascular Access System |
| Glaxosmithkline, LLC. | $198.98 | 2020-2023 | Benlysta |
| Horizon Therapeutics Plc | $197.29 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $195.97 | 2022-2024 | Lupkynis |
| Mallinckrodt Enterprises LLC | $141.25 | 2019 | |
| Fresenius USA Marketing, INC. | $125.03 | 2022-2025 | Velphoro, Velphoro, Korsuva |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $116.88 | 2019 | |
| Akebia Therapeutics INC | $92.04 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $88.70 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $82.78 | 2025 | |
| Recor Medical INC | $67.89 | 2025 | Paradise Ultrasound Renal Denervation System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.11 | 2025 | Jardiance |
| Shire North American Group INC | $35.84 | 2019 | |
| Ardelyx, INC. | $30.28 | 2023 | Ibsrela |
| Pfizer INC. | $29.58 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $25.72 | 2025 | |
| Alexion Pharmaceuticals, INC. | $25.71 | 2022 | |
| Scpharmaceuticals INC. | $23.32 | 2025 | |
| Genzyme Corporation | $19.17 | 2022 | |
| Novo Nordisk INC | $16.27 | 2025 | Ozempic |
| Tactile Systems Technology INC | $12.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devaraj Munikrishnappa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.